Multiple Myeloma

Choosing Between BCMA and Non-BCMA Bispecifics in Multiple Myeloma Treatment

A recent Satellite Sessions program hosted by CancerNetwork® brought together experts from different Ochsner Health campuses to discuss the diversity of practices among care providers regarding patient interactions and treatment choices.

Binod Dhakal, MD, MS;Joseph R. Mikhael, MD;Cindy Varga, MD;Beth Faiman, PhD, CNP;Jeremy Larsen, MD

Recent Data on Non-BCMA Targeting Bispecifics in R/R MM

Experts explain the strategies for optimal selection between different BCMA-targeting and non-BCMA-targeting bispecifics for the treatment of relapsed/refractory multiple myeloma.

Surbhi Sidana, MD;Melissa Alsina, MD; Maria-Victoria Mateos, MD, PhD;Jack Khouri, MD

Selecting and Sequencing Non-BCMA-Targeting Bispecifics in MM

Experts review recent data on non-BCMA-targeting bispecifics for the treatment of R/R MM.

Surbhi Sidana, MD;Melissa Alsina, MD; Maria-Victoria Mateos, MD, PhD;Jack Khouri, MD

Sequencing BCMA-Targeting Bispecifics in R/R MM Treatment

The panel discusses how non-BCMA-targeting bispecifics might be selected and sequenced in MM.

Binod Dhakal, MD, MS;Joseph R. Mikhael, MD;Cindy Varga, MD;Beth Faiman, PhD, CNP;Jeremy Larsen, MD

Multiple Myeloma: Addressing Financial Barriers to Bispecifics

Cindy Varga, MD, details her experience with sequencing BCMA-targeting agents for patients with relapsed/refractory multiple myeloma.

Cesar Rodriguez, MD;Scott A. Soefje, PharmD;Kirollos S. Hanna, PharmD, BCPS, BCOP, FACCC;Frances A. Bell, NP

Bispecifics in MM: mSMART Guidelines for Monitoring and Managing AEs

Key opinion leaders in multiple myeloma management address barriers inherent in the selection and use of bispecifics.

Rafael Fonseca, MD;Shaji Kumar, MD, Mayo Clinic;Joselle Cook, MBBS, Mayo Clinic;Morie A. Gertz, MD, MACP, Mayo Clinic

Pharmacists’ Perspectives on Initiating Bispecific Therapy in Multiple Myeloma

Focused discussion on the mSMART guidelines for monitoring and managing adverse events associated with bispecific therapies in patients being treated for relapsed/refractory multiple myeloma.

Cesar Rodriguez, MD;Scott A. Soefje, PharmD;Kirollos S. Hanna, PharmD, BCPS, BCOP, FACCC;Frances A. Bell, NP

Insights from Experts at Mayo Clinic: Step-up and Treatment Dosing of Bispecifics

Experts Scott A. Soefje, PharmD, and Kirollos S. Hanna, PharmD, share their perspectives on initial steps in initiating bispecific therapy for patients with multiple myeloma.

Rafael Fonseca, MD;Shaji Kumar, MD, Mayo Clinic;Joselle Cook, MBBS, Mayo Clinic;Morie A. Gertz, MD, MACP, Mayo Clinic

Subset Analysis of the MAIA Study in the Frail Multiple Myeloma Population

A panel of key opinion leaders from Mayo Clinic reflect on optimizing use of bispecifics in relapsed/refractory multiple myeloma, reviewing step-up dosing, administration, and followup strategies.

Natalia Neparidze, MD;Noffar Bar, MD;Elan Gorshein, DO, JD, MPH;Catherine Wei, MD;David Witt, MD;Syed S. Ali, MD

June 26th 2023

Experts comment on the subset analysis of the MAIA study in the frail NDMM patient population.

Treatment Approaches in Patients With Transplant-Ineligible NDMM

Natalia Neparidze, MD;Noffar Bar, MD;Elan Gorshein, DO, JD, MPH;Catherine Wei, MD;David Witt, MD;Syed S. Ali, MD

June 26th 2023

Noffar Bar, MD, discusses the MAIA study investigating a daratumumab combination therapy in patients with transplant-ineligible multiple myeloma.

Black Population Appears Less Likely to Meet Multiple Myeloma Trial Eligibility

Nicholas Wrigley;Hayley Virgil

Overview of Treatment Options for Relapsed/Refractory Multiple Myeloma

Black patients appear less likely than their White or Asian counterparts to meet hematologic lab criteria and treatment-related criteria necessary to enroll in clinical multiple myeloma trials.

Thomas G. Martin, MD;Ajay K. Nooka, MD;Jeremy Larsen, MD

Determining Transplant Ineligibility in Newly Diagnosed Multiple Myeloma

Key opinion leaders share comprehensive insight to the treatment armamentarium for patients with relapsed/refractory multiple myeloma.

Andrew P. Dalovisio, MD;Kelly Pippin, MD;Ryan P. Griffin, MD;Ernest C. Quintin, MD;Thomas Atkinson, MD

Features of High-Risk Multiple Myeloma and Clinical Trial Landscape

Focused discussion on factors that aid in determining transplant ineligibility when a patient presents with newly diagnosed multiple myeloma.

Al-Ola Abdallah, MD;Leyla O. Shune, MD;Nausheen Ahmed, MD;Jordan Snyder, PharmD

Treatment Options for Frontline and Relapsed Multiple Myeloma

The expert panel provides clinical insights on the key features of high-risk multiple myeloma and a look toward the clinical trial landscape.

C. Ola Landgren, MD, PhD;Dickran Kazandjian, MD;Benjamin Diamond, MD;Dennis Verducci, APRN

Overview of Cytokine Release Syndrome in Relapsed/Refractory Multiple Myeloma

An overview of multiple myeloma treatment options in the frontline and relapsed settings.

Thomas G. Martin, MD;Ajay K. Nooka, MD;Jeremy Larsen, MD

What is the Role of Transplant in Treating Patients With NDMM?

Experts Thomas Martin, MD; Ajay Nooka, MD; and Jeremy Larsen, MD, provide a broad overview of cytokine release syndrome as it relates to the management of multiple myeloma.

Andrew P. Dalovisio, MD;Kelly Pippin, MD;Ryan P. Griffin, MD;Ernest C. Quintin, MD;Thomas Atkinson, MD

Patient Monitoring and Workup in Relapsed MM

Key opinion leaders in multiple myeloma management reflect on the current role of stem cell transplant in patients with newly diagnosed disease.

C. Ola Landgren, MD, PhD;Dickran Kazandjian, MD;Benjamin Diamond, MD;Dennis Verducci, APRN

Role of Transplant in Multiple Myeloma

Experts on multiple myeloma discuss approaches to laboratory workup and patient monitoring at the time of relapse.

Al-Ola Abdallah, MD;Leyla O. Shune, MD;Nausheen Ahmed, MD;Jordan Snyder, PharmD

FDA Pauses CART-ddBCMA Trial in Relapsed/Refractory Multiple Myeloma

Clinical experts examine the role of transplant in multiple myeloma and discuss key clinical trials and the impact of adding daratumumab to triplet therapy.

$Patients with relapsed or refractory multiple myeloma who have already undergone lymphodepletion are able to continue receiving treatment with CART-ddBCMA in the phase 2 IMMagine-1 trial.$

Russ Conroy

Unmet Needs and Future Perspectives in Newly-Diagnosed and Relapsed Multiple Myeloma

Patients with relapsed or refractory multiple myeloma who have already undergone lymphodepletion are able to continue receiving treatment with CART-ddBCMA in the phase 2 IMMagine-1 trial.

Ashley Rosko, MD;Naresh Bumma, MD;Abdullah Khan, MBBS;April Logue, APRN-CNP;Barry Hammer, PA-C

CAR T-Cell Therapy vs Bispecific Antibodies for Patients With Refractory Multiple Myeloma

Closing out their discussion, the panel shares remaining unmet needs in the treatment of newly-diagnosed and relapsed multiple myeloma.

$CAR T-Cell Therapy vs Bispecific Antibodies for Patients With Refractory Multiple Myeloma$

Ashley Rosko, MD;Naresh Bumma, MD;Abdullah Khan, MBBS;April Logue, APRN-CNP;Barry Hammer, PA-C

Other Bispecific Antibodies Under Investigation for Treatment of Relapsed Multiple Myeloma

Naresh Bumma, MD, reviews how he selects between CAR T-cell therapy and bispecific agents for patients with refractory multiple myeloma.

Ashley Rosko, MD;Naresh Bumma, MD;Abdullah Khan, MBBS;April Logue, APRN-CNP;Barry Hammer, PA-C

Patient Case 3: A 52-Year-Old Treated with a Non-BCMA-Targeting Bispecific

Naresh Bumma, MD, details other bispecific agents on the horizon for relapsed multiple myeloma treatment.

Surbhi Sidana, MD;Melissa Alsina, MD; Maria-Victoria Mateos, MD, PhD;Jack Khouri, MD

Managing Infections and Other Toxicities Associated with Bispecifics in MM

Maria-Victoria Mateos, MD, PhD, presents the case of a 52-year-old patient with penta-exposed MM who receives treatment with a non-BCMA-targeting bispecific.

Binod Dhakal, MD, MS;Joseph R. Mikhael, MD;Cindy Varga, MD;Beth Faiman, PhD, CNP;Jeremy Larsen, MD

The Development of Bispecifics-Based Combination Therapies in MM

Jeremy Larsen, MD, discusses the management of infections, neurotoxicity, and other side effects associated with bispecifics in patients with R/R MM, including the need for prophylactic antimicrobials and monitoring of immunoglobulin levels.

Surbhi Sidana, MD;Melissa Alsina, MD; Maria-Victoria Mateos, MD, PhD;Jack Khouri, MD

Best Practices for Transition of Care in Patients with MM on Teclistamab

Dr Maria-Victoria Mateos shares her expert perspectives on current efficacy and safety data on combination strategies with bispecifics in relapsed/refractory MM.

Binod Dhakal, MD, MS;Joseph R. Mikhael, MD;Cindy Varga, MD;Beth Faiman, PhD, CNP;Jeremy Larsen, MD